Novartis lays off more in New York; DEA approves Xcelience to make Class 1 schedule drugs

> Florida-based CDMO Xcelience has been granted DEA approval to make Class I schedule drugs. Report

> Novartis ($NVS) will lay off 89 more workers starting June 30 at its Diovan plant in Suffern, NY. Report

> CDMO Recipharm has competed a serialization project in Korea for Abbott. Release

> Fusion Pharmaceuticals is recalling more than 9,400 Dicopanol kits for mixing diphenhydramine hydrochloride because of microbial contamination. Recall

> The Mississippi attorney general has asked a judge to keep the identity of the state's execution-drug supplier secret while he appeals an order to release the name. Story


Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.